Article

Levofloxacin approved for corneal ulcers

Levofloxacin ophthalmic solution 1.5% (Iquix, Vistakon) has been introduced for the treatment of corneal ulcers.

Jacksonville, FL-Levofloxacin ophthalmic solution 1.5% (Iquix) has been introduced for the treatment of corneal ulcers. It is the only newer-generation fluoroquinolone approved by the FDA for this indication, according to the Vistakon Pharmaceuticals LLC.

Vistakon is marketing the drop through a co-marketing agreement with Santen Inc. The drug is manufactured by Santen Oy, Tampere, Finland. The brand name is a licensed trademark of Daiichi-Sankyo Co. Ltd., Tokyo.

The sterile, preservative-free, topical formulation is designed to penetrate corneal tissue rapidly and provide broad coverage of the most sight-threatening gram-negative and the most prevalent gram-positive pathogens, including Corynebacterium species, Staphylococcus aureus, S epidermidis, Streptococcus pneumoniae, Viridans group streptococci, Pseudomonas aeruginosa, and Serratia marcescens.

"Compared [with] existing ophthalmic fluoroquinolones, [levofloxacin] offers a higher sustained concentration option," said Penny A. Asbell, MD, professor of ophthalmology and director of cornea services, external disease, and refractive surgery at Mount Sinai School of Medicine, New York. "This, paired with its dual mechanism of action, provides a new and important option for doctors' corneal ulcer treatment."

The drop is contraindicated in patients with histories of hypersensitivity to levofloxacin, to other quinolones, or to any of the components in the medication. The formulation was well-tolerated in clinical trials, according to the company. Ocular adverse events occurring in 1% to 2% of patients included decreased/blurred vision, instillation site irritation/discomfort, ocular infection, and ocular pain/discomfort. Non-ocular adverse events, occurring in approximately 8% to 10% of patients, were headache and taste disturbance.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.